Horizon Stock Dives As Guidance Boost Fails To Overcome Sales Miss
Horizon Therapeutics reported a mixed quarter Wednesday, but raised its sales target for 2021. Still, HZNP stock dipped after the open. Tepezza hit a supply disruption in the quarter.